Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data

Catherine S. Y. LecatDepartment of Haematology, University College London Hospitals, London, UK;

http://orcid.org/0000-0001-9233-6967

Caroline BesleyBristol Haematology & Oncology Centre, University Hospitals Bristol, Bristol, UK;

Rachael E. HoughDepartment of Haematology, University College London Hospitals, London, UK;

Asim KhwajaUCL Cancer Institute, London, UK

Caroline FurnessBristol Haematology & Oncology Centre, University Hospitals Bristol, Bristol, UK;

David I. MarksBristol Haematology & Oncology Centre, University Hospitals Bristol, Bristol, UK;

Adele K. FieldingUCL Cancer Institute, London, UKCorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Author contributions

CL and CB performed the research, AKF designed the research, CL and AKF analyzed the data and wrote the paper, REH, AK, CF, DM contributed patient data. All authors read and approved the final version.

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data

Information for

Open access

Opportunities

Help and information

Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia – real-world resource use data

Author contributions

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature